2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
134
Lung Neoplasms
50
Breast Neoplasms
24
Head and Neck Neoplasms
22
Adenocarcinoma of Lung
18
Brain Neoplasms
15
Neoplasms
14
Adenocarcinoma, Bronchiolo-Alveolar
11
Squamous Cell Carcinoma of Head and Neck
10
Glioblastoma
9
Esophageal Neoplasms
9
Colorectal Neoplasms
9
NSCLC
8
Rectal Neoplasms
7
Prostatic Neoplasms
7
Neoplasm Metastasis
7
Gliosarcoma
7
Colonic Neoplasms
7
Adenocarcinoma Of Esophagus
7
Ovarian Neoplasms
5
Esophageal Squamous Cell Carcinoma
5
Adenocarcinoma
5
Urinary Bladder Neoplasms
4
Central Nervous System Neoplasms
4
Carcinoma, Renal Cell
4
Carcinoma
4
Unspecified Adult Solid Tumor, Protocol Specific
3
Skin Neoplasms
3
Respiratory Tract Diseases
3
Kidney Neoplasms
3
Interventions
osimertinib
1
Gefitinib
1
Erlotinib Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
×
Gefitinib
×
Clear all
NCT02296125
2026-04-21
FLAURA
AstraZeneca
Phase 3
Completed
674 enrolled
21 charts
1 FDA